Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome)

Clinics in Chest Medicine

Volumn 38, Issue 1, 2017, Pages 71-86

  Hui, David S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clinical features; MERS CoV; Pathogenesis; Respiratory tract infections; SARS CoV; Treatment

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA2B INTERFERON PLUS RIBAVIRIN; BETA INTERFERON; BETA1A INTERFERON; CHLOROQUINE; CORTICOSTEROID; HYDROCORTISONE; INTERFERON BETA SERINE; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NITAZOXANIDE; PLACEBO; POLYCLONAL ANTIBODY; RIBAVIRIN; VIRUS ANTIBODY;

BAT; CHILL; CLINICAL FEATURE; CORONAVIRIDAE; COUGHING; DISEASE COURSE; DROMEDARY; DRUG PULSE THERAPY; DYSPNEA; EPIDEMIC; FEVER; HAND WASHING; HEADACHE; HUMAN; INFECTION CONTROL; LOADING DRUG DOSE; MALAISE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIXED INFECTION; MORTALITY RATE; MYALGIA; NONHUMAN; NOSE SMEAR; PANDEMIC; PATHOGENESIS; PLASMA TRANSFUSION; PROTECTIVE EQUIPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RIGOR; SARS CORONAVIRUS; SEROPREVALENCE; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; VIRUS TRANSMISSION; X-RAY COMPUTED TOMOGRAPHY; ZOONOSIS; ANIMAL; CORONAVIRUS INFECTIONS; PATHOGENICITY;

ANIMALS; CHIROPTERA; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 85007621961     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2016.11.007     Document Type: Review

References (146)

1. 1 Zumla, A., Chan, J.F., Azhar, E.I., et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15:5 (2016), 327–347.
2. 2 Drosten, C., Gunther, S., Preiser, W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1967–1976.
3. 3 Ksiazek, T.G., Erdman, D., Goldsmith, C.S., et al., SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1953–1966.
4. 4 Kuiken, T., Fouchier, R.A., Schutten, M., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 (2003), 263–270.
5. 5 Lee, N., Hui, D.S., Wu, A., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003), 1986–1994.
6. 6 Tsang, K.W., Ho, P.L., Ooi, G.C., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003), 1977–1985.
7. 7 Zhao, Z., Zhang, F., Xu, M., et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 52 (2003), 715–720.
8. 8 Xu, R.H., He, J.F., Evans, M.R., et al. Epidemiologic clues to SARS origin in China. Emerg Infect Dis 10 (2004), 1030–1037.
9. 9 Zhong, N.S., Zheng, B.J., Li, Y.M., et al. Epidemiology and cause of severe acute respiratory syndrome in Guangdong, People's Republic of China, in Feb 2003. Lancet 362 (2003), 1353–1358.
10. 10 Du, L., Qiu, J.C., Wang, M., et al. Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China. Zhonghua Liu Xing Bing Xue Za Zhi 25 (2004), 925–928.
11. 11 Guan, Y., Zheng, B.J., He, Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 (2003), 276–278.
12. 12 Wang, M., Yan, M., Xu, H., et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 11 (2005), 1860–1865.
13. 13 Song, H.D., Tu, C.C., Zhang, G.W., et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 102 (2005), 2430–2435.
14. 14 Lau, S.K., Woo, P.C., Li, K.S., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci 102 (2005), 14040–14045.
15. 15 Li, W., Shi, Z., Yu, M., et al. Bats are natural reserviors of SARS-like coronaviruses. Science 310 (2005), 676–679.
16. 16 Shi, Z., Hu, Z., A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 133 (2008), 74–87.
17. 17 Chan, P.K., To, K.F., Lo, A.W., et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol 74 (2004), 1–7.
18. 18 Simmons, G., Gosalia, D.N., Rennekamp, A.J., et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci 102 (2005), 11876–11881.
19. 19 Li, W., Moore, M.J., Vasilieva, N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003), 450–454.
20. 20 Imai, Y., Kuba, K., Rao, S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436 (2005), 112–116.
21. 21 Law, P.T., Wong, C.H., Au, T.C., et al. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol 86 (2005), 1921–1930.
22. 22 Tan, Y.J., Fielding, B.C., Goh, P.Y., et al. Over expression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol 78 (2004), 14043–14047.
23. 23 Nicholls, J.M., Poon, L.L., Lee, K.C., et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361 (2003), 1773–1778.
24. 24 Peiris, J.S., Chu, C.M., Cheng, V.C., et al., HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361 (2003), 1767–1772.
25. 25 Wong, C.K., Lam, C.W.K., Wu, A.K., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136 (2004), 95–103.
26. 26 Zhao, J., Zhao, J., Perlman, S., T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol 84:18 (2010), 9318–9325.
27. 27 Channappanavar, R., Fehr, A.R., Vijay, R., et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19:2 (2016), 181–193.
28. 28 Tang, F., Liu, W., Zhang, F., et al. IL-12 RB1 genetic variants contribute to human susceptibility to severe acute respiratory syndrome infection among Chinese. PLoS One, 3(5), 2008, e2183.
29. 29 Ip, W.K., Chan, K.H., Law, H.K., et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191:10 (2005), 1697–1704.
30. 30 Franks, T.J., Chong, P.Y., Chui, P., et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol 34 (2003), 743–748.
31. 31 Tse, G.M., To, K.F., Chan, P.K., et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 57 (2004), 260–265.
32. 32 Hsu, L.Y., Lee, C.C., Green, J.A., et al. Severe acute respiratory syndrome in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 9 (2003), 713–717.
33. 33 Booth, C.M., Matukas, L.M., Tomlinson, G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 (2003), 2801–2809.
34. 34 WHO. Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Available at: http://www.who.int/csr/sars/country/table2004_04_21/en/. Accessed July 2, 2016.
35. 35 Peiris, J.S., Yuen, K.Y., Osterhaus, A.D., et al. The severe acute respiratory syndrome. N Engl J Med 349 (2003), 2431–2441.
36. 36 Wong, R.S., Hui, D.S., Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 10 (2004), 339–341.
37. 37 Yu, I.T., Wong, T.W., Chiu, Y.L., et al. Temporal-spatial analysis of Severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 40 (2005), 1237–1243.
38. 38 Loon, S.C., Teoh, S.C., Oon, L.L., et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 88 (2004), 861–863.
39. 39 Yu, I.T., Li, Y., Wong, T.W., et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 350 (2004), 1731–1739.
40. 40 Chu, C.M., Cheng, V.C., Hung, I.F., et al. Viral load distribution in SARS outbreak. Emerg Infect Dis 11 (2005), 1882–1886.
41. 41 Yu, I.T., Qiu, H., Tse, L.A., et al. Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy. Clin Infect Dis 58:5 (2014), 683–686.
42. 42 Booth, T.F., Kournikakis, B., Bastien, N., et al. Detection of airborne Severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 191 (2005), 1472–1477.
43. 43 Leung, G.M., Hedley, A.J., Ho, L.M., et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 141 (2004), 662–673.
44. 44 Peiris, J.S., Lai, S.T., Poon, L.L., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003), 1319–1325.
45. 45 Leung, W.K., To, K.F., Chan, P.K., et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterol 125 (2003), 1011–1017.
46. 46 Hung, E.C., Chim, S.S., Chan, P.K., et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem 49 (2003), 2108–2109.
47. 47 Lau, K.K., Yu, W.C., Chu, C.M., et al. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 10 (2004), 342–344.
48. 48 Wong, K.C., Leung, K.S., Hui, M., Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. J Bone Joint Surg Am 85A (2003), 1339–1342.
49. 49 Hon, K.L., Leung, C.W., Cheng, W.T., et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 561 (2003), 1701–1703.
50. 50 Wong, S.F., Chow, K.M., Leung, T.N., et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 191 (2004), 292–297.
51. 51 Leung, G.M., Lim, W.W., Ho, L.M., et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect 134 (2006), 211–221.
52. 52 Hui, D.S., Wong, K.T., Antonio, G.E., et al. Severe Acute Respiratory Syndrome (SARS): correlation of clinical outcome and radiological features. Radiology 233 (2004), 579–585.
53. 53 Hui, D.S., Wong, P.C., Wang, C., Severe acute respiratory syndrome: clinical features and diagnosis. Respirol 8 (2003), S20–S24.
54. 54 Wong, R.S., Wu, A., To, K.F., et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Br Med J 326 (2003), 1358–1362.
55. 55 Wong, K.T., Antonio, G.E., Hui, D.S., et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 228 (2003), 401–406.
56. 56 Stroher, U., DiCaro, A., Li, Y., et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis 189 (2004), 1164–1167.
57. 57 Chu, C.M., Cheng, V.C., Hung, I.F., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004), 252–256.
58. 58 Chan, K.S., Lai, S.T., Chu, C.M., et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 9 (2003), 399–406.
59. 59 Cinatl, J., Morgenstern, B., Bauer, G., et al. Treatment of SARS with human interferons. Lancet 362 (2003), 293–294.
60. 60 Hensley, L.E., Fritz, L.E., Jahrling, P.B., et al. Interferon-β 1a and SARS coronavirus replication. Emerg Infect Dis 10 (2004), 317–319.
61. 61 Haagmans, B.L., Kuiken, T., Martina, B.E., et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10 (2004), 290–293.
62. 62 Loutfy, M.R., Blatt, L.M., Siminovitch, K.A., et al. Interferon Alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290 (2003), 3222–3228.
63. 63 Jiang, Y., Xu, J., Zhou, C., et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 171 (2005), 850–857.
64. 64 Sung, J.J., Wu, A., Joynt, G.M., et al. Severe Acute Respiratory Syndrome: report of treatment and outcome after a major outbreak. Thorax 59 (2004), 414–420.
65. 65 Tsang, O.T., Chau, T.N., Choi, K.W., et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 9 (2003), 1381–1387.
66. 66 Wang, H., Ding, Y., Li, X., et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 349 (2003), 507–508.
67. 67 Griffith, J.F., Antonio, G.E., Kumta, S.M., et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 235 (2005), 168–175.
68. 68 Lee, N., Allen Chan, K.C., Hui, D.S., et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31 (2004), 304–309.
69. 69 Soo, Y., Cheng, Y., Wong, R., et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10 (2004), 676–678.
70. 70 Cheng, Y., Wong, R., Soo, Y.O., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24 (2005), 44–46.
71. 71 Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., et al., Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211 (2015), 80–90.
72. 72 Yu, I.T., Xie, Z.H., Tsoi, K.K., et al. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others?. Clin Infect Dis 44 (2007), 1017–1025.
73. 73 Tran, K., Cimon, K., Severn, M., et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One, 7, 2012, e35797.
74. 74 Zaki, A.M., van Boheemen, S., Bestebroer, T.M., et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
75. 75 World Health Organization, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – Qatar. Disease Outbreak News, 2016 Available at: http://www.who.int/csr/don/29-june-2016-mers-qatar/en/ Accessed July 2, 2016.
76. 76 WHO. Middle East respiratory syndrome coronavirus case definition for reporting to WHO interim case definition 14 July 2015. Available at: http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/. Accessed July 2, 2016.
77. 77 Annan, A., Baldwin, H.J., Corman, V.M., et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 19 (2013), 456–459.
78. 78 Memish, Z.A., Mishra, N., Olival, K.J., et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 19 (2013), 1819–1823.
79. 79 Miguel, E., Perera, R.A., Baubekova, A., et al. Absence of Middle East respiratory syndrome coronavirus in Camelids, Kazakhstan, 2015. Emerg Infect Dis 22:3 (2016), 555–557.
80. 80 Chan, S.M., Damdinjav, B., Perera, R.A., et al. Absence of MERS-coronavirus in bactrian camels, southern Mongolia, November 2014. Emerg Infect Dis 21:7 (2015), 1269–1271.
81. 81 Hemida, M.G., Perera, R.A., Al Jassim, R.A., et al. Seroepidemiology of Middle East Respiratory Syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill, 19(23), 2014 pii: 20828.
82. 82 Hemida, M.G., Elmoslemany, A., Al-Hizab, F., et al. Dromedary camels and the transmission of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Transbound Emerg Dis, 2015, 10.1111/tbed.12401.
83. 83 Saad, M., Omrani, A.S., Baig, K., et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29 (2014), 301–306.
84. 84 Hijawi, B., Abdallat, M., Sayaydeh, A., et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 19:Suppl 1 (2013), S12–S18.
85. 85 Alraddadi, B.M., Watson, J.T., Almarashi, A., et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22:1 (2016), 49–55.
86. 86 Drosten, C., Meyer, B., Müller, M.A., et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 371:9 (2014), 828–835.
87. 87 Arwady, M.A., Alraddadi, B., Basler, C., et al. Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014. Emerg Infect Dis 22:8 (2016), 1395–1402.
88. 88 Müller, M.A., Meyer, B., Corman, V.M., et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis 15:5 (2015), 559–564.
89. 89 Assiri, A., McGeer, A., Perl, T.M., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369 (2013), 407–416.
90. 90 Oboho, I.K., Tomczyk, S.M., Al-Asmari, A.M., et al. 2014 MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med 372 (2015), 846–854.
91. 91 Hunter, J.C., Nguyen, D., Aden, B., et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis 22 (2016), 647–656.
92. 92 Korea Centers for Disease Control and Prevention, Middle east respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 6:4 (2015), 269–278.
93. 93 Oh, M.D., Choe, P.G., Oh, H.S., et al. Middle east respiratory sayndrome coronavirus superspreading event involving 81 persons, Korea 2015. J Korean Med Sci 30:11 (2015), 1701–1705.
94. 94 WHO. WHO recommends continuation of strong disease control measures to bring MERS-CoV outbreak in Republic of Korea to an end. News Release 13 June 2013. Available at: http://www.wpro.who.int/mediacentre/releases/2015/20150613/en/. Accessed June 14, 2015.
95. 95 Zumla, A., Hui, D.S., Infection control and MERS-CoV in health-care workers. Lancet 383:9932 (2014), 1869–1871.
96. 96 WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr, 5, 2013 pii: ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
97. 97 Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of middle east respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13 (2013), 752–761.
98. 98 Guery, B., Poissy, J., el Mansouf, L., et al. Clinical features and viral diagnosis of two cases of infection with middle east respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 381 (2013), 2265–2272.
99. 99 Memish, Z.A., Zumla, A.I., Al-Hakeem, R.F., et al. Family cluster of middle east respiratory syndrome coronavirus infections. N Engl J Med 368 (2013), 2487–2494.
100. 100 Algahtani, H., Subahi, A., Shirah, B., Neurological complications of middle east respiratory syndrome coronavirus: a report of two cases and review of the literature. Case Rep Neurol Med, 2016, 2016, 3502683.
101. 101 Assiri, A., Abedi, G.R., Almasry, M., et al. Middle east respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. Clin Infect Dis 63:7 (2016), 951–953.
102. 102 Alserehi, H., Wali, G., Alshukairi, A., et al. Impact of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis, 16, 2016, 105.
103. 103 Malik, A., El Masry, K.M., Ravi, M., et al. Middle east respiratory syndrome- coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013. Emerg Infect Dis 22:3 (2016), 515–517.
104. 104 Payne, D.C., Iblan, I., Alqasrawi, S., et al. Stillbirth during infection with Middle East respiratory syndrome coronavirus. J Infect Dis 209:12 (2014), 1870–1872.
105. 105 Drosten, C., Seilmaier, M., Corman, V.M., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 13 (2013), 745–751.
106. 106 Corman, V.M., Albarrak, A.M., Omrani, A.S., et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 62:4 (2016), 477–483.
107. 107 Ajlan, A.M., Ahyad, R.A., Jamjoom, L.G., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am J Roentgenol 203:4 (2014), 782–787.
108. 108 Raj, V.S., Mou, H., Smits, S.L., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
109. 109 Lu, G., Hu, Y., Wang, Q., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500 (2013), 227–231.
110. 110 Müller, M.A., Raj, V.S., Muth, D., et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio, 3(6), 2012 pii: e00515–12.
111. 111 Chan, J.F., Chan, K.H., Choi, G.K., et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 207 (2013), 1743–1752.
112. 112 de Wilde, A.H., Raj, V.S., Oudshoorn, D., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 94 (2013), 1749–1760.
113. 113 Falzarano, D., de Wit, E., Martellaro, C., et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep, 3, 2013, 1686.
114. 114 Chan, R.W., Chan, M.C., Agnihothram, S., et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 87 (2013), 6604–6614.
115. 115 Hocke, A.C., Becher, A., Knepper, J., et al. Emerging human middle east respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 188:7 (2013), 882–886.
116. 116 Faure, E., Poissy, J., Goffard, A., et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS One, 9(2), 2014, e88716.
117. 117 Poissy, J., Goffard, A., Parmentier-Decrucq, E., et al. Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases. J Clin Virol 61:2 (2014), 275–278.
118. 118 Park, W.B., Perera, R.A., Choe, P.G., et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis 21:12 (2015), 2186–2189.
119. 119 Payne, D.C., Iblan, I., Rha, B., et al. Persistence of antibodies against middle east respiratory syndrome coronavirus. Emerg Infect Dis 22:10 (2016), 1824–1826.
120. 120 Ng, D.L., Al Hosani, F., Keating, M.K., et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 186:3 (2016), 652–658.
121. 121 Cha, R.H., Yang, S.H., Moon, K.C., et al. A case report of a Middle East respiratory syndrome survivor with kidney biopsy results. J Korean Med Sci 31:4 (2016), 635–640.
122. 122 Zhou, J., Chu, H., Li, C., et al. Active replication of middle east respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 209:9 (2014), 1331–1342.
123. 123 Dyall, J., Coleman, C.M., Hart, B.J., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58:8 (2014), 4885–4893.
124. 124 De Wilde, A.H., Jochmans, D., Posthuma, C.C., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:8 (2014), 4875–4884.
125. 125 Falzarano, D., de Wit, E., Rasmussen, A.L., et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19:10 (2013), 1313–1317.
126. 126 Al-Tawfiq, J.A., Momattin, H., Dib, J., et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20 (2014), 42–46.
127. 127 Shalhoub, S., Farahat, F., Al-Jiffri, A., et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 70:7 (2015), 2129–2132.
128. 128 Omrani, A.S., Saad, M.M., Baig, K., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14:11 (2014), 1090–1095.
129. 129 Spanakis, N., Tsiodras, S., Haagmans, B.L., et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 44:6 (2014), 528–532.
130. 130 Rossignol, J.F., Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110 (2014), 94–103.
131. 131 Arabi, Y., Arifi, A.A., Balkhy, H.H., et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 160:6 (2014), 389–397.
132. 132 Hui, D.S., Lee, N., Chan, P.K., Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 98:3 (2013), 410–416.
133. 133 Chan, J.F., Chan, K.H., Kao, R.Y., et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67:6 (2013), 606–616.
134. 134 Chan, J.F., Yao, Y., Yeung, M.L., et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:12 (2015), 1904–1913.
135. 135 AlGhamdi, M., Mushtaq, F., Awn, N., et al. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant 15:4 (2015), 1101–1104.
136. 136 Tang, X.C., Agnihothram, S.S., Jiao, Y., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 111:19 (2014), E2018–E2026.
137. 137 Johnson, R.F., Bagci, U., Keith, L., et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490 (2016), 49–58.
138. 138 Corti, D., Zhao, J., Pedotti, M., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A 112:33 (2015), 10473–10478.
139. 139 Jiang, L., Wang, N., Zuo, T., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med, 6(234), 2014, 234ra59.
140. 140 Luke, T., Wu, H., Zhao, J., et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med, 8(326), 2016, 326ra21.
141. 141 Johnson, R.F., Via, L.E., Kumar, M.R., et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 485 (2015), 422–430.
142. 142 WHO. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected. Interim guidance. 2015. Available at: http://apps.who.int/iris/bitstream/10665/178529/1/WHO_MERS_Clinical_15.1_eng.pdf. Accessed July 3, 2015.
143. 143 Version 3.0 Treatment of MERS-CoV: information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients, 2015, Public Health England and ISARIC Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/459835/merscov_for_clinicians_sept2015.pdf Accessed September 5, 2015.
144. 144 Breban, R., Riou, J., Fontanet, A., Interhuman transmissibility of middle east respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382 (2013), 694–699.
145. 145 Hui, D.S., Zumla, A., Advancing priority research on the middle east respiratory syndrome coronavirus. J Infect Dis 209 (2014), 173–176.
146. 146 Menachery, V.D., Yount, B.L. Jr., Sims, A.C., et al. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A 113:11 (2016), 3048–3053.